GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sunesis Pharmaceuticals Inc (FRA:RYIS) » Definitions » Cyclically Adjusted PS Ratio

Sunesis Pharmaceuticals (FRA:RYIS) Cyclically Adjusted PS Ratio : (As of May. 11, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Sunesis Pharmaceuticals Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Sunesis Pharmaceuticals Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Sunesis Pharmaceuticals's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sunesis Pharmaceuticals Cyclically Adjusted PS Ratio Chart

Sunesis Pharmaceuticals Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Sunesis Pharmaceuticals Quarterly Data
Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Sunesis Pharmaceuticals's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Sunesis Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sunesis Pharmaceuticals's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sunesis Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Sunesis Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.



Sunesis Pharmaceuticals Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Sunesis Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2020 is calculated as:

For example, Sunesis Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Dec. 2020 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec. 2020 (Change)*Current CPI (Dec. 2020)
=0/109.8968*109.8968
=0.000

Current CPI (Dec. 2020) = 109.8968.

Sunesis Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201103 43.877 94.283 51.143
201106 0.000 95.235 0.000
201109 11.359 95.727 13.040
201112 0.000 95.213 0.000
201203 0.000 96.783 0.000
201206 18.672 96.819 21.194
201209 3.219 97.633 3.623
201212 21.657 96.871 24.569
201303 21.943 98.209 24.554
201306 20.944 98.518 23.363
201309 20.667 98.790 22.991
201312 19.622 98.326 21.931
201403 18.727 99.695 20.643
201406 17.429 100.560 19.047
201409 8.085 100.428 8.847
201412 7.734 99.070 8.579
201503 8.576 99.621 9.461
201506 7.687 100.684 8.390
201509 5.971 100.392 6.536
201512 5.913 99.792 6.512
201603 4.873 100.470 5.330
201606 4.602 101.688 4.973
201609 4.610 101.861 4.974
201612 4.057 101.863 4.377
201703 3.640 102.862 3.889
201706 0.000 103.349 0.000
201709 0.000 104.136 0.000
201712 0.000 104.011 0.000
201803 0.686 105.290 0.716
201806 0.000 106.317 0.000
201809 0.000 106.507 0.000
201812 0.000 105.998 0.000
201903 0.000 107.251 0.000
201906 0.000 108.070 0.000
201909 0.000 108.329 0.000
201912 0.585 108.420 0.593
202003 0.120 108.902 0.121
202006 0.000 108.767 0.000
202009 0.000 109.815 0.000
202012 0.000 109.897 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Sunesis Pharmaceuticals  (FRA:RYIS) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Sunesis Pharmaceuticals Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Sunesis Pharmaceuticals's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Sunesis Pharmaceuticals (FRA:RYIS) Business Description

Traded in Other Exchanges
N/A
Address
395 Oyster Point Boulevard, Suite 400, South San Francisco, CA, USA, 94080
Sunesis Pharmaceuticals Inc is a US-based biopharmaceutical company. It focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The product portfolio of the company includes Vosaroxin which is an anticancer quinolone derivative for the treatment of acute myeloid leukemia (AML). The company's other kinase inhibitor pipeline includes TAK-580, SNS-062, and SNS-229. Further, the firm's activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The firm derives substantially the majority of revenue from license and collaboration agreements.

Sunesis Pharmaceuticals (FRA:RYIS) Headlines

No Headlines